Cas9 Stable Cell Line - LNCaP clone FGC

The LNCaP clone FGC-Cas9 stable cell line is the preferred model for prostate cancer research. It is established by integrating the Cas9 nuclease into a human LNCaP clone FGC background. LNCaP is an adherent epithelial cell line isolated from the supraclavicular lymph node metastases of a 50-year-old male patient with prostate adenocarcinoma. A significant biological characteristic of LNCaP cells is their androgen sensitivity, as they express the androgen receptor (AR) and produce prostate-specific antigen (PSA). Constitutive expression of Cas9 in this cell line provides an efficient and reproducible platform for CRISPR-mediated gene editing, ensuring the continued availability of the editing mechanism. This stable system eliminates the variability of transient transfection and provides a powerful tool for studying the molecular genetics of androgen-dependent and castration-resistant prostate cancer (CRPC).

The primary applications of the LNCaP clone FGC-Cas9 stable cell line are in studying prostate cancer progression and identifying novel therapeutic targets in androgen signaling pathways. Researchers used this cell line for large-scale CRISPR screening to identify genes involved in androgen-independent transitions, resistance to anti-androgen therapy, and tumor metastasis mechanisms. The LNCaP-Cas9 cell line is particularly suitable for constructing homologous clones with specific gene knockouts, enabling scientists to study the roles of various co-regulatory factors and signaling modules in castration-resistant prostate cancer (CRPC). Furthermore, it serves as an important platform for evaluating the efficacy of targeted therapies and studying molecular pathways related to prostate cancer cell growth and apoptosis.